Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jan. (Comparative Effectiveness Reviews, No. 37.)

This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Chronic Kidney Disease Stages 1–3

Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment [Internet].

Contents

< PrevNext >

Appendix CEvidence Tables and Other Supporting Tables and Figures

Appendix Evidence Table C1. Overview of ACEI monotherapy versus control treatment trials (MS Word, 176K)

Appendix Table C2. Summary of study baseline characteristics for ACEI monotherapy versus control treatment trials (MS Word, 51K)

Appendix Table C3. Clinical outcomes (outcomes part A), ACEI monotherapy versus control treatment trials (MS Word, 143K)

Appendix Figure C1. Forest plots for ACEI monotherapy versus control treatment trials

Appendix Table C4. Clinical outcomes (outcomes part B), ACEI monotherapy versus control treatment trials (MS Word, 121K)

Appendix Table C5. Composite vascular outcome definitions for ACEI monotherapy versus control treatment trials (MS Word, 68K)

Appendix Table C6. Clinical renal outcomes (outcomes part C), ACEI monotherapy versus control treatment trials (MS Word, 109K)

Appendix Table C7. Composite renal outcome definitions for ACEI versus control treatment trials (MS Word, 62K)

Appendix Table C8. Study withdrawals and adverse events (outcomes Part D), ACEI monotherapy versus control treatment trials (MS Word, 119K)

Appendix Evidence Table C9. Overview of ARB monotherapy trials (MS Word, 82K)

Appendix Table C10. Summary of study baseline characteristics for ARB monotherapy trials (MS Word, 47K)

Appendix Table C11. Clinical outcomes (outcomes part A), ARB monotherapy trials (MS Word, 61K)

Appendix Figure C2. Forest plots for ARB monotherapy trials

Appendix Table C12. Clinical outcomes (outcomes part B), ARB monotherapy trials (MS Word, 61K)

Appendix Table C13. Composite vascular outcome definitions for ARB monotherapy trials (MS Word, 52K)

Appendix Table C14. Clinical renal outcomes (outcomes part C), ARB monotherapy trials (MS Word, 62K)

Appendix Table C15. Composite renal outcome definitions for ARB monotherapy trials (MS Word, 53K)

Appendix Table C16. Study withdrawals and adverse events (outcomes part D), ARB monotherapy trials (MS Word, 62K)

Appendix Table C17. Overview of ACEI plus ARB versus ACEI or ARB trials (n=6 trials) (MS Word, 74K)

Appendix Table C18. Summary of study baseline characteristics for ACEI plus ARB versus ACEI or ARB trials (MS Word, 20K)

Appendix Table C19. Clinical outcomes (outcomes part A), ACEI plus ARB versus ACEI or ARB trials (MS Word, 67K)

Appendix Table C20. Clinical outcomes (outcomespart B), ACEI plus ARB versus ACEI or ARB trials (MS Word, 61K)

No ACE+ARB versus ARB studies reported these outcomes

Appendix Figure C3. Forest plots for ACEI plus ARB versus ACEI trials

Appendix Table C21. Composite vascular outcome definitions for ACEI plus ARB versus ACEI or ARB trials (MS Word, 47K)

Appendix Table C22. Clinical renal outcomes (outcomes part C), ACEI plus ARB versus ACEI or ARB trials (MS Word, 64K)

Appendix Table C23. Composite renal outcome definitions for ACEI plus ARB versus ACEI or ARB trials (MS Word, 44K)

Appendix Table C24. Study withdrawals and adverse events (outcomes part D), ACEI plus ARB versus ACEI or ARB trials (MS Word, 70K)

Appendix Table C25. Overview of ACEI plus ARB versus ARB trials (n=3 trials) (MS Word, 57K)

Appendix Figure C4. Forest plots ACEI plus ARB versus ARB trials

Appendix Figure C5. Forest plots ACEI plus ARB versus ACEI or ARB trial

Appendix Evidence Table C26. Overview of ACEI plus ARB versus ACEI plus aldosterone antagonist trial (MS Word, 49K)

Appendix Table C27. Clinical outcomes (outcomes part A), ACEI plus ARB versus ACEI plus aldosterone antagonist trial (MS Word, 46K)

Appendix Figure C6. Forest plots for ACEI plus ARB versus ACEI plus aldosterone antagonist trial

Appendix Table C28. Clinical renal outcomes (outcomes part C), ACEI plus ARB versus ACEI plus aldosterone antagonist trial (MS Word, 46K)

Appendix Table C29. Study withdrawals and adverse events (outcomes part D), ACEI plus ARB versus ACEI plus aldosterone antagonist trial (MS Word, 47K)

Appendix Evidence Table C30. Overview of ACEI plus CCB versus ACEI monotherapy or CCB monotherapy trial (MS Word, 49K)

Appendix Table C31. Clinical outcomes (outcomes part A), ACEI plus CCB versus ACEI monotherapy or CCB monotherapy trial (MS Word, 46K)

Appendix Table C32. Clinical outcomes (outcomespart B), ACEI plus CCB versus ACEI monotherapy or CCB monotherapy trial (MS Word, 46K)

Appendix Figure C7. Forest plots for ACEI plus CCB versus ACE monotherapy trial

Appendix Figure C8. Forest plots for ACEI plus CCB versus CCB monotherapy trial

Appendix Table C33. Study withdrawals and adverse events (outcomes part D), ACEI plus CCB versus ACEI monotherapy or CCB monotherapy trial (MS Word, 47K)

Appendix Table C34. Overview of ACEI plus diuretic versus ACEI plus CCB trials (MS Word, 56K)

Appendix Table C35. Clinical outcomes (outcomes part A), ACEI plus diuretic versus ACEI plus CCB trials (MS Word, 48K)

Appendix Table C36. Clinical outcomes (outcomes part B), ACEI plus diuretic versus ACEI plus CCB trials (MS Word, 49K)

Appendix Table C37. Clinical renal outcomes (outcomes part C), ACEI plus diuretic versus ACEI plus CCB trials (MS Word, 49K)

Appendix Table 38. Composite renal outcome definition, ACEI plus diuretic versus ACEI plus CCB trials (MS Word, 46K)

Appendix Figure C9. Forest plots forACEI plus diuretic versus ACEI plus CCB trials

Appendix Table C39. Study withdrawals and adverse events (outcomes part D), ACEI plus diuretic versus ACEI plus CCB trials (MS Word, 49K)

Appendix Table C40. Overview of ACEI plus diuretic versus ACEI monotherapy trial (MS Word, 49K)

Appendix Table C41. Clinical outcomes (outcomes part B), ACEI plus diuretic versus ACEI monotherapy trial (MS Word, 46K)

Appendix Table C42. Composite vascular outcome definitions, ACEI plus diuretic versus ACEI monotherapy trial (MS Word, 46K)

Appendix Figure C10. Forest plot for ACEI plus diuretic versus ACEI monotherapy trial

Appendix Table C43. Study withdrawals and adverse events (outcomes part D), ACEI plus diuretic versus ACEI monotherapy trial (MS Word, 47K)

Appendix Evidence Table C44. Overview of ACEI plus diuretic versus placebo trial (MS Word, 50K)

Appendix Table C45. Clinical outcomes (outcomes part A), ACEI plus diuretic versus placebo trial (MS Word, 46K)

Appendix Table C46. Clinical outcomes (outcomes part B), ACEI plus diuretic versus placebo trial (MS Word, 46K)

Appendix Table C47. Composite vascular outcome definition, ACEI plus diuretic versus placebo trial (MS Word, 45K)

Appendix Table C48. Clinical outcomes (outcomes part C), ACEI plus diuretic versus placebo trial (MS Word, 46K)

Appendix Table C49. Composite renal outcome definitions, ACEI plus diuretic versus placebo trial (MS Word, 45K)

Appendix Figure C11. Forest plots for ACEI plus diuretic versus placebo trial

Appendix Table C50. Study withdrawals and adverse events (outcomes part D), ACEI plus diuretic versus placebo trial (MS Word, 46K)

Appendix Table C51. Overview of ARB versus ARB trials (MS Word, 67K)

Appendix Table C52. Summary of study baseline characteristics for ARB versus ARB studies (MS Word, 44K)

Appendix Table C53. Clinical outcomes (outcomes part A), ARB versus ARB trials (MS Word, 55K)

Appendix Table C54. Clinical outcomes (outcomes part B), ARB versus ARB trials (MS Word, 55K)

Appendix Table C55. Composite vascular outcome definitions, ARB versus ARB trials (MS Word, 48K)

Appendix Figure C12. Forest plots for ARB versus different ARB trials

Appendix Table C56. Clinical renal outcomes (outcomes part C), ARB versus ARB trials (MS Word, 55K)

Appendix Table C57. Composite renal outcome definitions, ARB versus ARB trials (MS Word, 48K)

Appendix Table C58. Study withdrawals and adverse events (outcomes part D), ARB versus ARB trials (MS Word, 57K)

Appendix Evidence Table C59. Overview of ACEI plus aldosterone antagonist versus ACEI trial (MS Word, 48K)

Appendix Table C60. Clinical outcomes (outcomes part A), ACEI plus aldosterone antagonist versus ACEI plus placebo trial (MS Word, 46K)

Appendix Table C61. Clinical outcomes (outcome part B), ACEI plus aldosterone antagonist versus ACEI plus placebo trial (MS Word, 46K)

Appendix Figure C13. Forest plots for ACEI plus aldosterone antagonist versus ACEI plus placebo trial

Appendix Table C62. Study withdrawals and adverse events (outcomes part D), ACEI plus aldosterone antagonist versus. ACEI plus placebo trials (MS Word, 47K)

Appendix Evidence Table C63. Overview of ACE/ARB plus aldosterone antagonist versus ACE/ARB plus placebo trial (MS Word, 48K)

Appendix Table C64. Clinical outcomes (outcomes part A), ACEI/ARB plus aldosterone antagonist versus ACEI/ARB plus placebo trial (MS Word, 46K)

Appendix Figure C14. Forest plot for ACEI/ARB plus aldosterone antagonist versus ACEI/ARB plus placebo trial

Appendix Table C65. Study withdrawals and adverse events (outcomes part D), ACEI/ARB plus aldosterone antagonist versus ACEI/ARB plus placebo trial (MS Word, 46K)

Appendix Evidence Table C66. Overview of BB versus placebo trials (MS Word, 56K)

Appendix Table C67. Clinical outcomes (outcomes part A), BB versus placebo trials (MS Word, 47K)

Appendix Table C68. Clinical outcomes (outcomes part B), BB versus placebo trials (MS Word, 48K)

Appendix Table C69. Composite vascular outcome definitions, BB versus placebo trials (MS Word, 47K)

Appendix Figure C15. Forest plots for BB versus placebo trials

Appendix Table C70. Study withdrawals and adverse events (outcomes part D), BB versus placebo trials (MS Word, 48K)

Appendix Evidence Table C71. Overview of CCB versus placebo trials (MS Word, 56K)

Appendix Table C72. Summary of study baseline characteristics, CCB versus placebo trials (MS Word, 44K)

Appendix Table C73. Clinical outcomes (outcomes part A), CCB versus placebo trials (MS Word, 50K)

Appendix Figure C16. Forest plots for CCB versus placebo trials

Appendix Table C74. Clinical outcomes (outcomes part B), CCB versus placebo trials (MS Word, 50K)

Appendix Table C75. Composite vascular outcome definitions, CCB versus placebo trials (MS Word, 48K)

Appendix Table C76. Clinical renal outcomes (outcomes part C), CCB versus placebo trials (MS Word, 50K)

Appendix Table C77. Composite renal outcome definitions, CCB versus placebo trials (MS Word, 47K)

Appendix Table C78. Study withdrawals and adverse events (outcomes part D), CCB versus placebo trials (MS Word, 51K)

Appendix Evidence Table C79. Overview of diuretic versus placebo trial (MS Word, 48K)

Appendix Table C80. Clinical outcomes (outcomes part A), diuretic versus placebo trial (MS Word, 46K)

Appendix Table C81. Clinical outcomes (outcomes part B), diuretic versus placebo trial (MS Word, 46K)

Appendix Figure C17. Forest plots for diuretic versus placebo trial

Appendix Table C82. Composite vascular outcome definitions, diuretic versus placebo trial (MS Word, 45K)

Appendix Table C83. Study withdrawals and adverse events (outcomes part D), diuretic versus placebo trial (MS Word, 46K)

Appendix Evidence Table C84. Overview of ACEI versus conventional therapy without ACEI trial (MS Word, 48K)

Appendix Table C85. Clinical outcomes (outcomes part A), ACEI versus conventional therapy without ACEI trial (MS Word, 46K)

Appendix Table C86. Clinical renal outcomes (outcomes part C), ACEI versus conventional therapy without ACEI trial (MS Word, 46K)

Appendix Table C87. Composite renal outcome definitions, ACEI versus conventional therapy without ACEI trial (MS Word, 45K)

Appendix Figure C18. Forest plots for ACEI versus conventional therapy without ACEI trial

Appendix Table C88. Study withdrawals and adverse events (outcomes part D), ACEI versus conventional therapy without ACEI trial (MS Word, 46K)

Appendix Table C89. Overview of CCB versus BB trials (MS Word, 60K)

Appendix Table C90. Summary of study baseline characteristics, CCB versus BB trials (MS Word, 44K)

Appendix Table C91. Clinical outcomes (outcomes part A), CCB versus BB trials (MS Word, 53K)

Appendix Table C92. Clinical outcomes (outcomes part B), CCB versus BB trials (MS Word, 49K)

Appendix Table C93. Composite vascular outcome definitions, CCB versus BB trials (MS Word, 48K)

Appendix Figure C19. Forest plots for CCB versus BB trials

Appendix Table C94. Clinical renal outcomes (outcomes part C), CCB versus BB trials (MS Word, 51K)

Appendix Table C95. Composite renal outcome definitions, CCB versus BB trials (MS Word, 46K)

Appendix Table C96. Study withdrawals and adverse events (outcomes part D), CCB versus BB trials (MS Word, 52K)

Appendix Table C97. Overview of CCB versus diuretic trial (MS Word, 51K)

Appendix Table C98. Summary of study baseline characteristics, CCB versus diuretic trial (MS Word, 44K)

Appendix Table C99. Clinical outcomes (outcomes part A), CCB versus diuretic trial (MS Word, 46K)

Appendix Table C100. Clinical outcomes (outcomes part B), CCB versus diuretic trial (MS Word, 46K)

Appendix Table C101. Composite vascular outcome definitions, CCB versus diuretic trial (MS Word, 46K)

Appendix Table C102. Clinical renal outcomes (outcomes part C), CCB versus diuretic trial (MS Word, 47K)

Appendix Table C103. Composite renal outcome definitions, CCB versus diuretic trial (MS Word, 46K)

Appendix Figure C20. Forest plots for CCB versus diuretic trial

Appendix Table C104. Overview of strict versus standard blood pressure control trials (MS Word, 81K)

Appendix Table C105. Summary of study baseline characteristics, strict versus standard blood pressure control trials (MS Word, 45K)

Appendix Table C106. Clinical outcomes (outcomes part A), strict versus standard blood pressure control trials (MS Word, 61K)

Appendix Figure C21. Forest plots for strict versus standard blood pressure control trials

Appendix Table C107. Clinical outcomes (outcomes part B), strict versus standard blood pressure control trials (MS Word, 61K)

Appendix Table C108. Composite vascular outcome definitions, strict versus standard blood pressure control trial (MS Word, 46K)

Appendix Table C109. Clinical renal outcomes (outcomes part C), strict versus standard blood pressure control trials (MS Word, 61K)

Appendix Table C110. Composite renal outcome definitions, strict versus standard blood pressure control trials (MS Word, 47K)

Appendix Table C111. Study withdrawals and adverse events (outcomes part D), strict versus standard blood pressure control trials (MS Word, 63K)

Appendix Table C112. Overview of low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 84K)

Appendix Table C113. Summary of study baseline characteristics for low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 47K)

Appendix Table C114. Clinical outcomes (outcomes part A), low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 66K)

Appendix Figure C22. Forest plots for low protein diet versus usual protein diet and other dietary intervention trials

Appendix Table C115. Clinical outcomes (outcomes part B), low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 65K)

Appendix Table C116. Clinical renal outcomes (outcomes part C), low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 66K)

Appendix Table C117. Composite renal outcome definitions, low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 46K)

Appendix Table C118. Study withdrawals and adverse events (outcomes part D), low protein diet versus usual protein diet and other dietary intervention trials (MS Word, 68K)

Appendix Evidence Table C119. Overview of glycemic control trials (MS Word, 53K)

Appendix Table C120. Summary of study baseline characteristics for glycemic control trials (MS Word, 44K)

Appendix Table C121. Clinical outcomes (outcomes part A), glycemic control trials (MS Word, 48K)

Appendix Table C122. Clinical renal outcomes (outcomes part C), glycemic control trials (MS Word, 48K)

Appendix Figure C23. Forest plot for glycemic control trials

Appendix Table C123. Study withdrawals and adverse events (outcomes part D), glycemic control trials (MS Word, 48K)

Appendix Table C124. Overview of anti-lipid trials (MS Word, 127K)

Appendix Table C125. Summary of study baseline characteristics, anti-lipid (AL) monotherapy versus control treatment trials (MS Word, 50K)

Appendix Table C126. Clinical outcomes (outcomes part A), AL monotherapy versus control treatment trials (MS Word, 83K)

Appendix Figure C24. Forest plots for anti-lipid monotherapy versus control trials

Appendix Table C127. Clinical outcomes (outcomes part B), AL monotherapy versus control treatment trials (MS Word, 83K)

Appendix Table C128. Composite vascular outcome definitions, AL monotherapy versus control treatment trials (MS Word, 73K)

Appendix Table C129. Clinical renal outcomes (outcomes part C), AL monotherapy versus control treatment trials (MS Word, 81K)

Appendix Table C130. Composite renal outcome definitions for AL monotherapy versus control treatment trials (MS Word, 46K)

Appendix Table C131. Study withdrawals and adverse events (outcomes part D), AL monotherapy versus control treatment trials (MS Word, 86K)

Appendix Evidence Table C132. Overview of intensive multicomponent intervention (INT) versus control treatment trials (MS Word, 63K)

Appendix Table C133. Summary of study baseline characteristics for INT versus control treatment trials (MS Word, 45K)

Appendix Table C134. Clinical outcomes (outcomes part A), INT versus control treatment trials (MS Word, 53K)

Appendix Figure C25. Forest plots for INT versus control treatment trials

Appendix Table C135. Clinical outcomes (outcomes part B), INT versus control treatment trials (MS Word, 53K)

Appendix Table C136. Composite vascular outcome definitions for INT versus control treatment trials (MS Word, 51K)

Appendix Table C137. Clinical renal outcomes (outcomes part C), INT versus control treatment trials (MS Word, 53K)

Appendix Table C138. Composite renal outcome definitions for INT versus control treatment trials (MS Word, 45K)

Appendix Table C139. Study withdrawals and adverse events (outcomes part D), INT versus control treatment trials (MS Word, 53K)

Table C140. Assessment of individual study quality for KQ5 and KQ6 (MS Word, 271K)

References for Appendix C

1.: Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. Journal of the American Society of Nephrology. 2007 Oct;18(10):2766–72. [PubMed: 17804673]
2.: Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004 Nov 2;110(18):2809–16. [PubMed: 15492322]
3.: Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004 Feb 28;328(7438):495. [Erratum appears in BMJ. 2004 Mar 20; 328(7441):686] [PMC free article: PMC351842] [PubMed: 14960504]
4.: Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Research & Clinical Practice. 2002 Feb;55(2):113–21. [Erratum appears in Diabetes Res Clin Pract 2002 Jul;57(1):71] [PubMed: 11796177]
5.: Bojestig M, Karlberg BE, Lindstrom T, et al. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care. 2001 May;24(5):919–24. [PubMed: 11347755]
6.: Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 Jul 25;286(4):421–6. [PubMed: 11466120]
7.: O'Hare P, Bilbous R, Mitchell T, et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000 Dec;23(12):1823–9. [PubMed: 11128360]
8.: Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Current Therapeutic Research - Clinical and Experimental. 1999 Dec;60(12):650–60. 1999.
9.: Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999 Jul 31;354(9176):359–64. [PubMed: 10437863]
10.: Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 1998 Jan;21(1):104–10. [PubMed: 9538979]
11.: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997 Jun 28;349(9069):1857–63. [PubMed: 9217756]
12.: Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine. 1996 Apr 11;334(15):939–45. [PubMed: 8596594]
13.: Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. American Journal of Hypertension. 1995 Sep;8(9):876–83. [PubMed: 8541002]
14.: Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. American Journal of Medicine. 1995 Nov;99(5):497–504. [PubMed: 7485207]
15.: Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994 May;17(5):420–4. [PubMed: 8062609]
16.: Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine. 1993 Nov 11;329(20):1456–62. [Erratum appears in N Engl J Med 1993 Jan 13;330(2):152] [PubMed: 8413456]
17.: Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Annals of Internal Medicine. 1993 Apr 15;118(8):577–81. [PubMed: 8452322]
18.: Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16;372(9638):547–53. [PubMed: 18707986]
19.: Menne J, Farsang C, Deak L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. Journal of Hypertension. 2008 Sep;26(9):1860–7. [PubMed: 18698222]
20.: Sengul AM, Altuntas Y, Kurklu A, et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Research & Clinical Practice. 2006 Feb;71(2):210–9. [PubMed: 16112244]
21.: Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine. 2004 Nov 4;351(19):1952–61. [Erratum appears in N Engl J Med. 2005 Apr 21;352(16)1731] [PubMed: 15516696]
22.: Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney International. 2000 Aug;58(2):762–9. [PubMed: 10916100]
23.: Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine. 2005 Apr 25;165(8):936–46. [PubMed: 15851647]
24.: Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. American Journal of Hypertension. 2002 Dec;15(12):1042–9. [PubMed: 12460699]
25.: Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 6;285(21):2719–28. [PubMed: 11386927]
26.: Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421–31. [Erratum appears in JAMA. 2006 Jun 21;295(23):2726] [PubMed: 12435255]
27.: Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases. 2006 Nov;48(5):739–51. [PubMed: 17059993]
28.: Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. Journal of Hypertension. 2001 Oct;19(10):1871–6. [PubMed: 11593109]
29.: Zucchelli P, Zuccala A, Gaggi R. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrology Dialysis Transplantation. 1995 Oct;10 Suppl 9:46–51. [PubMed: 8643208]
30.: Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney International. 1992 Aug;42(2):452–8. [PubMed: 1405330]
31.: van Essen GG, Apperloo AJ, Rensma PL, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney International - Supplement. 1997 Dec;63:S58–62. [PubMed: 9407423]
32.: Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994 Oct 1;309(6958):833–7. [PMC free article: PMC2541105] [PubMed: 7950612]
33.: Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. Journal of Hypertension. 2004 Aug;22(8):1613–22. [PubMed: 15257186]
34.: Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Annals of Internal Medicine. 2006 Feb 7;144(3):172–80. [Summary for patients in Ann Intern Med. 2006 Feb 7;144(3):I33; PMID: 16461958] [PubMed: 16461961]
35.: Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011 Mar 15;123(10):1098–107. [PubMed: 21357827]
36.: Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine. 2000 Jan 20;342(3):145–53. [PubMed: 10639539]
37.: Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007 Jun;30(6):1577–8. [PubMed: 17389334]
38.: Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine. 2001 Sep 20;345(12):861–9. [PubMed: 11565518]
39.: Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine. 2001 Sep 20;345(12):870–8. [PubMed: 11565519]
40.: Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine. 2001 Sep 20;345(12):851–60. [PubMed: 11565517]
41.: Saruta T, Hayashi K, Ogihara T, et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. Hypertension Research - Clinical & Experimental. 2009 Jun;32(6):505–12. [PubMed: 19390535]
42.: Ogawa S, Takeuchi K, Mori T, et al. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertension Research - Clinical & Experimental. 2007 Apr;30(4):325–34. [PubMed: 17541211]
43.: Viberti G, Wheeldon NM., MicroAlbuminuria Reduction With VSI. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 Aug 6;106(6):672–8. [PubMed: 12163426]
44.: Kanno Y, Takenaka T, Nakamura T, et al. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clinical Journal of The American Society of Nephrology: CJASN. 2006 Jul;1(4):730–7. [PubMed: 17699280]
45.: Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology. 2009 Dec;20(12):2641–50. [PMC free article: PMC2794224] [PubMed: 19926893]
46.: Anand IS, Bishu K, Rector TS, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009 Oct 20;120(16):1577–84. [PubMed: 19805651]
47.: Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney International. 2008 Jun;73(11):1303–9. [PubMed: 18354383]
48.: Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 3;375(9721):1173–81. [PubMed: 20170948]
49.: Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004 Sep;17(9):793–801. [PubMed: 15363822]
50.: Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension. 2003 May;41(5):1063–71. [PubMed: 12654706]
51.: Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010 Aug;21(8):1355–60. [PMC free article: PMC2938598] [PubMed: 20634296]
52.: Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia. 2001 Sep;44(9):1118–20. [PubMed: 11596665]
53.: Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International. 2008 Aug;74(3):364–9. [PubMed: 18496508]
54.: Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrology Dialysis Transplantation. 2008 Oct;23(10):3174–83. [PubMed: 18450829]
55.: Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. Journal of the American Society of Nephrology. 2009 Apr;20(4):893–900. [PMC free article: PMC2663827] [PubMed: 19211712]
56.: van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. Journal of Hypertension. 2006 Nov;24(11):2285–92. [PubMed: 17053552]
57.: Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail. 2009 Sep;11(9):872–80. [PMC free article: PMC2729679] [PubMed: 19648605]
58.: Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215–25. [PubMed: 15642700]
59.: Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). Journal of Cardiac Failure. 2009 May;15(4):310–8. [PubMed: 19398079]
60.: Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine. 2003 Apr 1;138(7):542–9. [Summary for patients in Ann Intern Med. 2003 Apr 1;138(7):I43; PMID: 12667050] [PubMed: 12667024]
61.: Pahor M, Shorr RI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Archives of Internal Medicine. 1998 Jun 22;158(12):1340–5. [PubMed: 9645829]
62.: Cinotti GA, Zucchelli PC., Collaborative Study G. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrology Dialysis Transplantation. 2001 May;16(5):961–6. [PubMed: 11328901]
63.: Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney International. 1996 Nov;50(5):1641–50. [PubMed: 8914031]
64.: Wright JT Jr, Kusek JW, Toto RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials. 1996 Aug;17(4 Suppl):3S–16S. [PubMed: 8889350]
65.: Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366(9489):895–906. [PubMed: 16154016]
66.: Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005 Mar 12-18;365(9463):939–46. [PubMed: 15766995]
67.: Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000 Apr;23 Suppl 2:B54–64. [PubMed: 10860192]
68.: Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002 Mar;61(3):1086–97. [PubMed: 11849464]
69.: Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. American Journal of Kidney Diseases. 1999 Nov;34(5):809–17. [PubMed: 10561135]
70.: Toto RD, Mitchell HC, Smith RD, et al. “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney International. 1995 Sep;48(3):851–9. [PubMed: 7474675]
71.: Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Annals of Internal Medicine. 1995 Nov 15;123(10):754–62. [PubMed: 7574193]
72.: Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New England Journal of Medicine. 1994 Mar 31;330(13):877–84. [PubMed: 8114857]
73.: Greene T, Bourgoignie JJ, Habwe V, et al. Baseline characteristics in the Modification of Diet in Renal Disease Study. Journal of the American Society of Nephrology. 1993 Nov;4(5):1221–36. [Republished from J Am Soc Nephrol 1993 May;3(11):1819-34] [PubMed: 8305650]
74.: Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989 May;13(5 Suppl):I80–93. [PubMed: 2490833]
75.: Koya D, Haneda M, Inomata S, et al. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia. 2009 Oct;52(10):2037–45. [PMC free article: PMC2744830] [PubMed: 19652945]
76.: Dussol B, Iovanna C, Raccah D, et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. Journal of Renal Nutrition. 2005 Oct;15(4):398–406. [PubMed: 16198932]
77.: Kopple JD, Levey AS, Greene T, et al. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney International. 1997 Sep;52(3):778–91. [PubMed: 9291200]
78.: D'Amico G, Gentile MG, Fellin G, et al. Effect of dietary protein restriction on the progression of renal failure: a prospective randomized trial. Nephrology Dialysis Transplantation. 1994;9(11):1590–4. [PubMed: 7870348]
79.: Locatelli F, Alberti D, Graziani G, et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991 Jun 1;337(8753):1299–304. [PubMed: 1674294]
80.: Rosman JB, Langer K, Brandl M, et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney International - Supplement. 1989 Nov;27:S96–102. [PubMed: 2636680]
81.: Rosman JB, ter Wee PM, Meijer S, et al. Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet. 1984 Dec 8;2(8415):1291–6. [PubMed: 6150320]
82.: Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes. 2003 May;52(5):1204–9. [PubMed: 12716753]
83.: Williams PS, Stevens ME, Fass G, et al. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. Quarterly Journal of Medicine. 1991 Oct;81(294):837–55. [PubMed: 1801057]
84.: Samuelsson O, Attman PO, Knight-Gibson C, et al. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron. 1997;75(3):286–94. [PubMed: 9069450]
85.: Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine. 2009 Jan 8;360(2):129–39. [PubMed: 19092145]
86.: Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ. 1995 Oct 14;311(7011):973–7. [PMC free article: PMC2550986] [PubMed: 7580637]
87.: Kendrick J, Shlipak MG, Targher G, et al. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases. 2010 Jan;55(1):42–9. [PMC free article: PMC2803327] [PubMed: 19932541]
88.: Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010 Mar 23;55(12):1266–73. [PubMed: 20206456]
89.: Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009 Oct;206(2):512–7. [PubMed: 19423108]
90.: Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases. 2009 Nov;54(5):810–9. [PubMed: 19540640]
91.: Koren MJ, Davidson MH, Wilson DJ, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases. 2009 May;53(5):741–50. [PubMed: 19216014]
92.: Isaacsohn JL, Davidson MH, Hunninghake D, et al. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000 Jul 15;86(2):250–2. [PubMed: 10913499]
93.: Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Kidney Diseases. 2008 Sep;52(3):412–24. [PMC free article: PMC2897819] [PubMed: 18676075]
94.: Chonchol M, Cook T, Kjekshus J, et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases. 2007 Mar;49(3):373–82. [PubMed: 17336698]
95.: Huskey J, Lindenfeld J, Cook T, et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis. 2009 Jul;205(1):202–6. [PubMed: 19124121]
96.: Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine. 2007 Nov 29;357(22):2248–61. [PubMed: 17984166]
97.: Lemos PA, Serruys PW, de Feyter P, et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology. 2005 Feb 15;95(4):445–51. [PubMed: 15695126]
98.: Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004 Sep 21;110(12):1557–63. [PubMed: 15364796]
99.: Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine. 2003 Jan 21;138(2):98–104. [Summary for patients in Ann Intern Med. 2003 Jan 21;138(2):I28; PMID:12529112] [PubMed: 12529091]
100.: Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010 Nov 13;376(9753):1658–69. [PMC free article: PMC2988223] [PubMed: 21067805]
101.: Shepherd J, Kastelein JJP, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology. 2008 Apr 15;51(15):1448–54. [PubMed: 18402899]
102.: LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 7;352(14):1425–35. [PubMed: 15755765]
103.: Waters DD, Guyton JR, Herrington DM, et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004 Jan 15;93(2):154–8. [PubMed: 14715339]
104.: Tonolo G, Velussi M, Brocco E, et al. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney International. 2006 Jul;70(1):177–86. [PubMed: 16710349]
105.: Chan JC, So WY, Yeung CY, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care. 2009 Jun;32(6):977–82. [PMC free article: PMC2681013] [PubMed: 19460913]
106.: Joss N, Ferguson C, Brown C, et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. Qjm. 2004 Apr;97(4):219–27. [PubMed: 15028852]
107.: Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine. 2003 Jan 30;348(5):383–93. [PubMed: 12556541]
108.: Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999 Feb 20;353(9153):617–22. [PubMed: 10030326]
109.: Harris LE, Luft FC, Rudy DW, et al. Effects of multidisciplinary case management in patients with chronic renal insufficiency. American Journal of Medicine. 1998 Dec;105(6):464–71. [PubMed: 9870830]
110.: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981–97. [PubMed: 12479763]

Copyright Notice

Bookshelf ID: NBK84565

< PrevNext >

Views

PubReader
Print View
Cite this Page
Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jan. (Comparative Effectiveness Reviews, No. 37.) Appendix C, Evidence Tables and Other Supporting Tables and Figures.
PDF version of this title (7.3M)

Other titles in these collections

Recent Activity

Clear Turn Off Turn On

Evidence Tables and Other Supporting Tables and Figures - Chronic Kidney Disease...
Evidence Tables and Other Supporting Tables and Figures - Chronic Kidney Disease Stages 1–3
Streptomyces roseus strain NPDC048552 NPDC048552_97_D3.ctg-0208, whole genome sh...
Streptomyces roseus strain NPDC048552 NPDC048552_97_D3.ctg-0208, whole genome shotgun sequence
gi|2761784157|ref|NZ_JBEZIN01000020 gnl|WGS:NZ_JBEZIN01|NPDC048552_97_D3.ctg-0208
Nucleotide
Streptomyces roseus strain NPDC048552 NPDC048552_97_D3.ctg-0199, whole genome sh...
Streptomyces roseus strain NPDC048552 NPDC048552_97_D3.ctg-0199, whole genome shotgun sequence
gi|2761784131|ref|NZ_JBEZIN01000019 gnl|WGS:NZ_JBEZIN01|NPDC048552_97_D3.ctg-0199
Nucleotide
Streptomyces roseus strain NPDC048552 NPDC048552_97_D3.ctg-0202, whole genome sh...
Streptomyces roseus strain NPDC048552 NPDC048552_97_D3.ctg-0202, whole genome shotgun sequence
gi|2761784140|ref|NZ_JBEZIN01000020 gnl|WGS:NZ_JBEZIN01|NPDC048552_97_D3.ctg-0202
Nucleotide
Chain A, SYNAPTOTAGMIN III
Chain A, SYNAPTOTAGMIN III
gi|6980525|pdb|1DQV|A
Protein

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on